2020 has marked a significant year for the cannabis market. With the pandemic leading to increased use of recreational and medicinal cannabis, Germany hit a symbolic milestone for medical cannabis activity, with over 100,000 patients applying for reimbursement from their insurers since the start of the medical cannabis program in early 2017.
One special winner of the November elections was cannabis. Voters in 5 states showed strong support for reform of cannabis laws for both medical and adult-use. This momentum has been hugely positive for the cannabis space as a whole and a big re-rate of the industry has taken a place through November. In addition to this tailwind, momentum continues with the passing of the MORE Act in the US House of Congress and although the vote was expected to pass in the Democrat controlled House, the hastiness of the legislation being voted upon was entirely unanticipated as the Democrats have yet to formally move into the White House.
At the beginning of December, the UN voted on the reclassification of cannabis as a deadly substance. Although it only passed with a slim margin of 27 to 25, it is expected to be highly influential as many governments look at global conventions for drug policy guidance.
We’ll be joined by Nawan Butt, Portfolio Manager at Purpose Investments to discuss:
• The UN deschedules cannabis creating policy guidance for UN nations
• Canadians re-invigorate focus towards Europe
• US legislators increasingly look to push for federal cannabis reform
For professional investors only. Capital at risk.